Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
2024年11月4日，汉口银行发行的第117期同业存单（CD117）受到了市场的广泛关注。据金融界数据披露，该同业存单在现券市场的交易量达到了1.3000亿元，成交净价为97.93元，收益率为2.0701%，并较前一交易日下跌了7.99个基点。对于投资者来说，这一消息不仅关乎汉口银行的资本运作，也直接影响了同业存单市场的整体表现。 首先，值得注意的是，汉口银行CD117的发行背景。该存单于2024 ...
Jasper Therapeutics, Inc. ( (JSPR) ) has released its Q3 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented ...
CD117 (Kit) or C-Kit is a growth factor receptor on mast cells. When a molecule called stem cell factor attaches to C-Kit, the development of mast cells results. A mutation of the receptor causes ...
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
6d
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American ...
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company ...
▎药明康德内容团队编辑今日，JasperTherapeutics公布其进行中SPOTLIGHT临床1b/2a期研究的初步数据。分析显示，慢性诱发性荨麻疹（CIndU）患者在接受其在研药物briquilimab皮下注射后1周便观察到完全缓解（CR），且 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback